Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Free Report) had its price objective reduced by B. Riley from $4.00 to $3.00 in a report published on Friday morning,Benzinga reports. They currently have a buy rating on the stock. B. Riley also issued estimates for Lineage Cell Therapeutics’ Q1 2025 earnings at ($0.03) EPS, Q2 2025 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.03) EPS and FY2027 earnings at ($0.08) EPS.
Several other brokerages also recently issued reports on LCTX. HC Wainwright reiterated a “buy” rating and set a $9.00 price objective on shares of Lineage Cell Therapeutics in a research report on Tuesday, March 11th. D. Boral Capital reiterated a “buy” rating and set a $2.00 price target on shares of Lineage Cell Therapeutics in a research report on Tuesday, March 11th. Finally, Maxim Group lowered their price target on Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a report on Friday, January 10th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Lineage Cell Therapeutics presently has an average rating of “Buy” and an average target price of $4.20.
Check Out Our Latest Report on Lineage Cell Therapeutics
Lineage Cell Therapeutics Price Performance
Institutional Investors Weigh In On Lineage Cell Therapeutics
Hedge funds and other institutional investors have recently bought and sold shares of the business. GSA Capital Partners LLP acquired a new stake in shares of Lineage Cell Therapeutics during the 3rd quarter valued at $84,000. MAI Capital Management lifted its holdings in shares of Lineage Cell Therapeutics by 2.2% during the third quarter. MAI Capital Management now owns 1,674,679 shares of the company’s stock valued at $1,516,000 after purchasing an additional 35,907 shares during the last quarter. Raffles Associates LP boosted its position in shares of Lineage Cell Therapeutics by 3.4% in the 3rd quarter. Raffles Associates LP now owns 4,507,781 shares of the company’s stock valued at $4,081,000 after purchasing an additional 150,000 shares during the period. State Street Corp increased its stake in Lineage Cell Therapeutics by 1.8% in the 3rd quarter. State Street Corp now owns 2,608,352 shares of the company’s stock worth $2,361,000 after purchasing an additional 45,483 shares in the last quarter. Finally, Barclays PLC raised its holdings in Lineage Cell Therapeutics by 311.3% during the 3rd quarter. Barclays PLC now owns 211,300 shares of the company’s stock worth $192,000 after buying an additional 159,924 shares during the period. 62.47% of the stock is currently owned by institutional investors.
Lineage Cell Therapeutics Company Profile
Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.
Read More
- Five stocks we like better than Lineage Cell Therapeutics
- Are Penny Stocks a Good Fit for Your Portfolio?
- How to Build the Ultimate Everything ETF Portfolio
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- How to Plot Fibonacci Price Inflection Levels
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Lineage Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lineage Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.